Core Viewpoint - Beijing Resources (00618) has reported a significant turnaround in its financial performance for the six months ending September 30, 2025, achieving a profit of approximately RMB 1.88 billion, driven by strategic asset sales and a focus on core business areas [1] Financial Performance - The company achieved total revenue of approximately RMB 810 million, representing a year-on-year growth of 8.1% [1] - The profit turnaround was primarily due to the sale of certain property development projects, generating approximately RMB 2.31 billion in revenue [1] - The company has improved its financial health, with interest-bearing loans reduced to RMB 253 million and a current ratio improved to 1.29 [1] Business Focus - The company has optimized its business structure, concentrating on two core areas: healthcare and pharmaceutical retail, as well as e-commerce and distribution [1] - E-commerce revenue reached RMB 430 million, reflecting a year-on-year increase of 37.1% [1] - The healthcare and pharmaceutical retail segment generated approximately RMB 70 million in revenue, with initiatives to advance the "pharmacy + traditional Chinese medicine" model and digital transformation [1] Corporate Actions - In August 2025, the company completed the establishment of a partnership with a third party, injecting certain property projects and streamlining its organizational structure to reduce liabilities [1] - The board of directors has decided not to recommend the distribution of an interim dividend [1]

Group 1 - The company, Beijing Resources (00618), has entered into a partnership agreement with Suzhou Aozhe and Chongqing Jingjiahui to establish a partnership enterprise with a total capital contribution of RMB 100,010,000 [1][2] - The capital contributions are as follows: Suzhou Aozhe contributes RMB 10,000, the company contributes RMB 30 million, and Chongqing Jingjiahui contributes RMB 70 million [1][2] - The main purpose of the partnership enterprise is to invest in special opportunity assets and related collective investment tools, as well as to explore project opportunities related to the healthcare industry for ideal investment returns [1] Group 2 - The company being sold primarily engages in investment holding and includes 17 subsidiaries, with 7 actively involved in property development in China [2] - The partnership agreement will introduce a professional asset manager to oversee post-investment management, inventory clearance, and debt restructuring of existing property development projects [2] - The transaction is expected to significantly reduce the company's debt levels and improve its financial condition, aligning with the company's strategic focus on optimizing resource allocation towards more promising sectors such as healthcare and retail [2]